Skip to main content

Table 1 Clinical and pathological data of IBC and non-IBC patients

From: Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways

Characteristic

IBC (N = 13)

Non-IBC (N = 17)

P value

Age

 Range

29–60

35–63

0.119a

 Mean ± SD

45.15 ± 8.98

50.11 ± 9.43

 NA

0

0

Tumor size

  ≤ 4

2 (16.7%)

2 (11.8%)

1.000b

  > 4

10 (83.3%)

15 (88.2%)

 NA

1

0

Lymph node status

  < 4

1 (10%)

7 (41.2%)

0.098b

  ≥ 4

9 (90%)

10 (58.8%)

 NA

3

0

Tumor grade

 G1

0

0

0.332b

 G2

7 (58.3%)

14 (82.4%)

 G3

4 (33.3%)

3 (17.6%)

 G4

1 (8.3%)

0

 NA

1

0

Lymphovascular invasion

 Negative

3 (27.3%)

13 (76.5%)

0.018*b

 Positive

8 (72.7%)

4 (23.5%)

 NA

2

0

  1. Data are expressed as mean ± SD
  2. NA Data not available
  3. *significant P value calculated by aStudent’s t-test or bFisher’s exact test